Q BioMed Inc. (QBIO)
- Previous Close
0.0004 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0004 - 52 Week Range
0.0000 - 0.0405 - Volume
5,000 - Avg. Volume
3,749 - Market Cap (intraday)
58,038 - Beta (5Y Monthly) 79.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Jun 4, 2024 - Jun 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
www.qbiomed.comRecent News: QBIO
Performance Overview: QBIO
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QBIO
Valuation Measures
Market Cap
87.06k
Enterprise Value
9.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.19
Price/Book (mrq)
--
Enterprise Value/Revenue
44.61
Enterprise Value/EBITDA
11.50
Financial Highlights
Profitability and Income Statement
Profit Margin
-231.77%
Return on Assets (ttm)
-85.13%
Return on Equity (ttm)
--
Revenue (ttm)
209.29k
Net Income Avi to Common (ttm)
-1.91M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
23.17k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.96M